Hossein Borghaei
Fox Chase Cancer Center · SWOG Cancer Research Network · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hossein Borghaei as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:49 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07854769 · Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung CancerFox Chase Cancer Center · not yet recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT05400577 · Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLCFox Chase Cancer Center · withdrawn · Non-Small Cell Lung Cancer · principal investigator
- Ph2/Ph3NCT03851445 · Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerSWOG Cancer Research Network · recruiting · Previously Treated Non-Small Cell Lung Cancer · study chair
- Ph3NCT03793179 · Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerNational Cancer Institute (NCI) · active not recruiting · Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8 · principal investigator
- Ph2NCT03527108 · Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLCFox Chase Cancer Center · active not recruiting · Non Small Cell Lung Cancer · principal investigator
- N/ANCT02132884 · Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerFox Chase Cancer Center · terminated · Malignant Pericardial Effusion, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer · principal investigator
- N/ANCT01840150 · Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung CancerFox Chase Cancer Center · completed · Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT01471964 · Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung CancerFox Chase Cancer Center · terminated · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent · principal investigator
- Ph2NCT00553800 · Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung CancerFox Chase Cancer Center · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · fiscal years 2016 to 2026 · $204,156 awarded in 2026Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT03793179
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:49 UTC. The ranking covers the 200 most relevant of 38 PubMed records, and a shared surname and initials can bring in a namesake. All 38 on PubMed
- 7,991 citationsRCR 252.7
- 2,515 citationsRCR 83.3
- Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 20192,327 citationsRCR 84.6
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation.N Engl J Med · 20211,561 citationsRCR 84.2
- 1,193 citationsRCR 35.0
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.Lancet Oncol · 2017797 citationsRCR 23.4
- 732 citationsRCR 21.9
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.J Clin Oncol · 2021568 citationsRCR 28.4
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.Lancet Oncol · 2016533 citationsRCR 16.5
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.N Engl J Med · 2023529 citationsRCR 41.5